Scarica l'app Stockscreener
3.84
2.67%
0.10
Dopo l'orario di chiusura:
3.80
-0.04
-1.04%
Fulcrum Therapeutics Inc Borsa (FULC) Ultime notizie
Fulcrum Therapeutics (NASDAQ: FULC) backs $245M migraine venture with Slate - Stock Titan
Fulcrum Therapeutics to Merge With Slate Medicines in $245 Million Backed Migraine Play - finance.biggo.com
Shareholder Alert: Ademi LLP investigates whether Fulcrum Therapeutics, Inc. is obtaining a Fair Price for Public Shareholders - PR Newswire
Fulcrum Therapeutics Strikes All-Stock Merger With Slate Medicines - Benzinga
Slate Medicines goes public via Fulcrum merger to challenge PACAP migraine field - AllSci
Fulcrum Therapeutics & Slate Medicines Merge for Next-Generation Migraine Therapies - Yahoo Finance
Fulcrum Therapeutics shutting down reverse merger with Slate Medicines - The Business Journals
Fulcrum Therapeutics Target of Unusually Large Options Trading (NASDAQ:FULC) - MarketBeat
Fulcrum Therapeutics and Slate Medicines to merge, refocusing combined company on migraine pipeline - thepharmaletter.com
Fulcrum Therapeutics stock rises on Slate Medicines merger deal - Investing.com
Fulcrum to merge with Slate in all-stock deal after drug setback - reuters.com
Fulcrum Therapeutics Merges With Slate in $245M Migraine Biotech Deal - MarketBeat
Transcript : Fulcrum Therapeutics, Inc., Slate Medicines, Inc.M&A Call - marketscreener.com
Form 8K Fulcrum Therapeutics Inc For: 17 August By Investing.com - Investing.com UK
Fulcrum (NASDAQ: FULC) investors get cash but small stake post‑Slate deal - Stock Titan
Fulcrum Therapeutics to Merge With Slate Medicines in Stock Deal Backed by $245 Million Financing - TradingView
Why is Fulcrum Therapeutics stock rallying today? - Investing.com
Fulcrum Therapeutics to merge with Slate Medicines in $245M deal - Investing.com Australia
Fulcrum Therapeutics and Slate Medicines Announce Merger Agreement to Advance Next-Generation Migraine Therapies - The Manila Times
Therapeutics, Inc. (FULC) RA Capital group now reports 0.0% stake - Stock Titan
Therapeutics, Inc. (FULC) 8.22% stake disclosed by Nantahala Capital - Stock Titan
Fulcrum Therapeutics (FULC): Montanova and affiliates report 5.5% ownership stake - Stock Titan
Fulcrum Therapeutics (FULC) investor group reduces reported ownership to 0% - Stock Titan
Kaplan Fox Investigates Fulcrum Therapeutics After 51% Stock Plunge Following Pociredir Program Halt - Kalkine Media
Assenagon Asset Management S.A. Has $3.06 Million Position in Fulcrum Therapeutics, Inc. $FULC - MarketBeat
Kaplan Fox Reminds Investors of Fulcrum Therapeutics, Inc. (NASDA - The National Law Review
Kaplan Fox is Investigating Fulcrum Therapeutics, Inc. (NASDAQ: FULC) for Potential Securities Law Violations - FinancialContent
Kaplan Fox Launches Securities Probe into Fulcrum Therapeutics Following 51% Stock Plunge After Pociredir Program Halt - Kalkine Media
Fulcrum Therapeutics Faces Securities Law Investigation After Pociredir Program Discontinuation Triggers 51% Stock Drop - kalkine.ca
Kaplan Fox Encourages Investors of Fulcrum Therapeutics, Inc. (NA - The National Law Review
Fulcrum Therapeutics stock plunges 51% after FD... - Pluang
Fulcrum Therapeutics Appoints Alan Musso as Principal Accounting Officer Amid Leadership Change - Kalkine Media
Form 8K Fulcrum Therapeutics Inc For: 10 August By Investing.com - Investing.com Australia
Fulcrum Therapeutics appoints Alan Musso as principal accounting officer By Investing.com - Investing.com Nigeria
Fulcrum Therapeutics appoints Alan Musso as principal accounting officer - Investing.com
Fulcrum Therapeutics, Inc. Appoints Alan Musso as Principal Accounting Officer, Effective August 7, 2026 - marketscreener.com
Fulcrum Therapeutics Inc (FULC) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
BofA Securities Maintains Fulcrum Therapeutics(FULC.US) With Sell Rating, Maintains Target Price $3 - Moomoo
FULC Stock Slumps Nearly 50% After Hours As FDA Kills Only Clinical Program Over Cancer Risk - Stocktwits
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Consensus Recommendation of "Reduce" from Analysts - MarketBeat
Fulcrum Therapeutics Stock Drops 51% After Pociredir Discontinuation as Law Firm Launches Securities Investigation - kalkine.ca
Fulcrum Therapeutics (FULC) Stock Sees Modest Fair Value Lift After Pociredir Exit - Yahoo Finance
Bank of America (NYSE: BAC) reports 6.7% holding in Fulcrum Therapeutics (FULC) - Stock Titan
Fulcrum Therapeutics stock plunges 51% after ha... - Pluang
Fulcrum Therapeutics (FULC) Gets a Hold from Truist Financial - The Globe and Mail
Truist Financial Downgrades Fulcrum Therapeutics(FULC.US) to Hold Rating, Cuts Target Price to $4 - Moomoo
Fulcrum Therapeutics (NASDAQ:FULC) Posts Earnings Results, Misses Expectations By $0.13 EPS - MarketBeat
Fulcrum Therapeutics (NASDAQ: FULC) ends pociredir, explores alternatives - Stock Titan
Kaplan Fox Initiates Securities Probe into Fulcrum Therapeutics After Halting Pociredir Program Amid FDA Safety Concerns - Kalkine Media
Kaplan Fox Launches Securities Investigation into Fulcrum Therapeutics Following Pociredir Program Discontinuation - kalkine.ca
BlackRock discloses 7.2% ownership of Therapeutics Inc (FULC) in updated filing - Stock Titan
Fulcrum Therapeutics Inc (FULC) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Fulcrum Therapeutics Inc (FULC) Institutional Confidence - TradingKey
Fulcrum Therapeutics Inc (FULC) Valuation: PE, PB & Fair Value Analysis - TradingKey
Kaplan Fox Launches Securities Probe Into Fulcrum Therapeutics After Pociredir Program Halt Sparks Stock Plunge - Kalkine Media
Fulcrum Therapeutics Inc (FULC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Fulcrum Therapeutics Inc (FULC) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Fulcrum Therapeutics Inc (FULC) Risk Assessment: Volatility, Financial Risk & Investment Risk - tradingkey.com
Fulcrum Therapeutics Inc (FULC) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Fulcrum Therapeutics, Inc. Revenue Breakdown – NASDAQ:FULC - TradingView
ETFs Investing in Fulcrum Therapeutics, Inc. Stocks - TradingView
Fulcrum Therapeutics Inc (FULC) Cash Flow - TradingKey
FULC|Fulcrum Therapeutics Inc|Price:3.725|Chg%:+0.005 - TradingKey
Kaplan Fox Encourages Investors of Fulcrum Therapeutics, Inc. (FULC) Who Suffered Losses to Contact the Firm Regarding a Securities Investigation - TMX Newsfile
Siren L.L.C. Increases Position in Fulcrum Therapeutics, Inc. $FULC - MarketBeat
Kaplan Fox is Investigating Fulcrum Therapeutics, Inc. (NASDAQ: F - The National Law Review
1.80%
1.77%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):